

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT PURSUANT TO
SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported) April 26, 2006

BECTON, DICKINSON AND COMPANY

(Exact Name of Registrant as Specified in Its Charter)

New Jersey

(State or Other Jurisdiction of Incorporation)

001-4802

22-0760120

(Commission File Number)

(IRS Employer Identification No.)

1 Becton Drive, Franklin Lakes, New Jersey

07417-1880

(Address of Principal Executive Offices)

(Zip Code)

(201) 847-6800

(Registrant's Telephone Number, Including Area Code)

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K Filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

ITEM 2.02 RESULTS OF OPERATIONS AND FINANCIAL CONDITION.

On April 26, 2006, Becton, Dickinson and Company ("BD") issued a press release announcing its financial results for the second fiscal quarter of fiscal year 2006. A copy of the press release is furnished as Exhibit 99.1 to this report.

The press release furnished as Exhibit 99.1 contains certain financial measures that differ from those presented in accordance with U.S. generally accepted principles (GAAP), as follows:

- Revenues. We present revenue growth rates at constant foreign exchange rates. We believe that presenting growth rates at constant foreign exchange rates allows investors to view the underlying operating results of BD and of its segments without the impact of fluctuations in foreign currency exchange rates, thereby facilitating comparisons to prior periods.
- Selling and Administrative Expense. We present selling and administrative expense, both alone and as a percentage of revenues, after excluding the impact of insurance settlements occurring during the period presented. As these settlements are not part of ordinary operations, management believes that these adjusted measures are more indicative of BD's underlying performance. Management also presents these adjusted measures in order to assist investors in comparing BD's selling and administrative expense for the period to prior periods.
- Research and Development Expense. We present research and development expense, both alone and as a percentage of revenues, after excluding the impact of the in-process research and development charge relating to the acquisition of GeneOhm Sciences Inc. ("GeneOhm"). As this non-cash charge is not part of ordinary operations and serves to increase research and development expense for the period, management believes that these adjusted measures are more indicative of BD's underlying performance. Management also presents these adjusted measures in order to assist investors in comparing BD's research and development expense for the period to prior periods.
- Operating Income. We present BD's operating income, both alone and as a percentage of revenues, after excluding the impact of insurance settlements and the in-process research and development charge relating to the GeneOhm acquisition. Management believes that these adjusted measures of operating income are more indicative of BD's underlying performance, and also allow investors to better understand BD's comparative operating performance for the period presented.
- Income Taxes/Effective Tax Rate. We present income taxes and effective tax rate after excluding the impact of insurance settlements. Since these items are not part of ordinary operations, management believes these adjusted measures are more indicative of BD's underlying performance and facilitate comparisons to prior periods.

We also present income taxes and effective tax rate for the prior year's period after excluding the effects of significant reversals of tax reserves and the effects of changes in tax laws and regulations and other events that caused the tax rate for the period presented to vary from BD's then expected effective tax rate for the full year. Significant reversals of tax reserves and the items mentioned above that effect our periodic effective tax rate cause fluctuations in BD's income from continuing operations from period to period that management believes are unrelated to BD's underlying operating performance. Accordingly, management believes that providing the impact of such effects allows investors to better understand BD's comparative operating performance for the periods presented.

- Income from Continuing Operations. We present operating income from continuing operations, both alone and as a percentage of revenues, after excluding the impact of insurance settlements and the in-process research and development charge relating to the GeneOhm acquisition. Since these items are not part of ordinary operations, management believes that these adjusted measures are more indicative of BD's underlying performance and also allow investors to better understand BD's comparative operating performance for the period presented.

We also present income from operations for the prior year's first six months after excluding the effects of significant reversals of tax reserves and the effects of changes in tax laws and regulations and other events that caused the tax rate for the quarter to vary from BD's then expected effective tax rate for the full year. For the reasons discussed above, management believes that providing the impact of such effects allows investors to better understand BD's comparative operating performance for the periods presented.

- Earnings Per Share. We present earnings per share from continuing operations, both for the periods presented and on a prospective basis, after excluding the impact of insurance settlements and the in-process research and development charge relating to the GeneOhm acquisition. Since these items are not part of ordinary operations, management believes that these adjusted measures of earnings per share from continuing operations are more indicative of BD's underlying performance and also allow investors to better understand BD's comparative operating performance for the periods presented.

We also present earnings per share from continuing operations on a prospective basis after excluding the aforementioned settlements and charge and the dilutive impact of the GeneOhm acquisition. Management excludes the impact of the GeneOhm operations in order to improve the comparability of the period presented to prior periods where such impact was not recorded.

We also present earnings per share from continuing operations for prior periods after excluding (i) the effects of significant reversals of tax reserves, (ii) the effects of changes in tax laws and regulations and other events that caused the tax rate during the period to vary from BD's expected effective tax rate for the full year, and/or (iii) the impact on taxes of the planned repatriation of foreign earnings under the provisions of the American Jobs Creation Act. These items cause fluctuations in BD's operating results that management believes are unrelated to BD's underlying operating performance. Accordingly, management believes that providing the impact of such items allows investors to better understand BD's comparative operating performance for the periods presented.

BD's management uses each of these non-GAAP measures in its own evaluation of BD's performance, particularly when comparing performance to past periods. Management also uses the non-GAAP results for budget planning purposes on a quarterly and annual basis.

Non-GAAP results should not be considered in isolation and are not in accordance with, or a substitute for, GAAP results. Our non-GAAP results may differ from similar measures used by other companies, even if similar terms are used to identify such measures. Although BD's management believes non-GAAP results are useful in evaluating the performance of its business, its reliance on these measures is limited since items excluded from such measures may have a material impact on BD's net income, earnings per share or cash flows calculated in accordance with GAAP. Therefore, management typically uses non-GAAP results in conjunction with GAAP results to address these limitations. Investors should also consider these limitations when evaluating BD's results.

BD provides non-GAAP measures to investors on a supplemental basis, as they provide additional insight into BD's financial results. Management believes the non-GAAP results provide a reasonable measure of BD's underlying performance before the effects of items that are considered by management to be outside of BD's underlying operational results or that affect period to period comparability.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.

Exhibits. — Exhibit 99.1 Press release dated April 26, 2006, which is furnished pursuant to Item 2.02.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BECTON, DICKINSON AND COMPANY
(Registrant)

By: /s/ Dean J. Paranicas
Dean J. Paranicas
Vice President, Corporate
Secretary and Public Policy

Date: April 26, 2006

INDEX TO EXHIBITS

Exhibit
Number

Description of Exhibits

99.1

Press release dated April 26, 2006, which is furnished pursuant to Item 2.02.

News Release



Contact:

Patricia A. Spinella, Investor Relations – 201-847-5453
Colleen T. White, Corporate Communications – 201-847-5369

BD ANNOUNCES RESULTS FOR SECOND FISCAL QUARTER

Franklin Lakes, NJ (April 26, 2006)– BD (Becton, Dickinson and Company) (NYSE: BDX) today reported record quarterly revenues of \$1.449 billion for the second fiscal quarter ended March 31, 2006, representing an increase of 6 percent over the prior year period. This quarter’s growth rate reflects an overall estimated 3 percent unfavorable impact from foreign currency translation, which affected all segments.

“We are very pleased with our strong second quarter results, which exceeded our expectations,” said Edward J. Ludwig, Chairman, President and Chief Executive Officer. “We also closed the acquisition of GeneOhm, which will enable BD to further progress in the emerging field of healthcare-associated infections. The Company is well positioned to become a leader in the prevention and management of this global healthcare problem.”

GeneOhm Sciences, Inc. Acquisition Completed

On February 14, 2006, BD announced the completion of its acquisition of GeneOhm Sciences, Inc. (GeneOhm), a company that has pioneered the development of molecular diagnostic testing for the rapid detection of bacteria, which cause healthcare-associated infections. Diluted earnings per share from continuing operations for the second quarter reflects a reduction of 1 cent per share related to the impact of GeneOhm operations for the second quarter. For the full fiscal year 2006, the Company expects diluted earnings per share from continuing operations to be reduced by approximately 7 cents related to the impact of GeneOhm operations. In addition, in the second quarter, the Company recorded an in-process research and development charge of \$53 million associated with the acquisition, which further reduced diluted earnings per share from continuing operations by 21 cents in the quarter (see Table 1).

Analysis of Second Quarter and Six-month Period of Fiscal Year 2006 and 2005 Earnings

The following analysis of diluted earnings per share from continuing operations for the second quarter and six-month period of fiscal 2006 and 2005 identifies specified items that affect the comparability of results between periods.

(Table 1)	Three Months Ended March 31,			Six Months Ended March 31,		
	FY2006	FY2005	% Incr./(Decr.)	FY2006	FY2005	% Incr.
Diluted EPS from Continuing Operations:⁽¹⁾	\$ 0.60	\$ 0.71	-15%	\$ 1.45	\$ 1.45	0%
Specified Items:						
Insurance Settlements ⁽²⁾	(0.02)	—		(0.04)	—	
In-Process Research and Development Charge ⁽³⁾	0.21	—		0.21	—	
Tax Examinations ⁽⁴⁾	—	—		—	(0.04)	
Tax Rate Impact ⁽⁵⁾	—	—		—	(0.02)	
Rounding	—	—		—	(0.01)	
	0.19	—		0.17	(0.07)	
Diluted EPS from Continuing Operations Excluding Specified Items:⁽¹⁾	\$ 0.79	\$ 0.71	11%	\$ 1.62	\$ 1.38	17%

- (1) Includes the effect on diluted earnings per share from continuing operations of a 1 cent reduction in the second quarter and the six-month period ended March 31, 2006 relating to GeneOhm operations.
- (2) Represents the effect on diluted earnings per share from continuing operations of 2 cents in each of the first and second quarter of fiscal 2006 related to proceeds received from insurance settlements regarding the Company's previously owned latex glove business.
- (3) Represents the effect on diluted earnings per share from continuing operations of the in-process research and development charge recorded in the second quarter of fiscal 2006 related to the GeneOhm acquisition.
- (4) Represents the effect on diluted earnings per share from continuing operations of the reversal of tax reserves in the first fiscal quarter of 2005 in connection with the conclusion of tax examinations in four non-U.S. jurisdictions.
- (5) Represents the effect on diluted earnings per share from continuing operations of tax-related events that caused the quarterly tax rate to vary from the then expected effective tax rate for fiscal year 2005.

As illustrated in Table 1, diluted earnings per share from continuing operations, excluding specified items and including the dilutive impact on operating results from the acquisition, of 79 cents for the second fiscal quarter of 2006 increased by 11 percent over diluted earnings per share from continuing operations of 71 cents for the second fiscal quarter of 2005. For the six-month period, diluted earnings per share from continuing operations, excluding specified items and including the dilutive impact on operating results from the acquisition, of \$1.62 for fiscal 2006 increased by 17 percent over diluted earnings per share from continuing operations, excluding specified items, of \$1.38 for fiscal 2005.

Segment Results

In the BD Medical segment, worldwide revenues for the quarter were \$795 million, representing an increase of 9 percent from the prior year period. Strong sales in the Diabetes Care and Pharmaceutical Systems units contributed to the growth of the segment. U.S. sales of safety-engineered products totaled \$123 million compared with \$115 million in the prior year's quarter. The growth rate of safety-engineered products benefited, in part, from a favorable comparison to the prior year's revenues, which were negatively impacted by reductions in inventory by a major U.S. distributor. For the six-month period ended March 31, 2006, U.S. sales of safety-engineered products totaled \$255 million compared with \$241 million in the prior year's period. Included in BD Medical revenues were international sales of safety-engineered products of \$22 million compared with \$21 million in the prior year's quarter. For the six-month period ended March 31, 2006, international sales of safety-engineered products totaled \$44 million compared with \$39 million in the prior year's period. For the six-month period ended March 31, 2006, the BD Medical segment reported 10 percent revenue growth.

In the BD Diagnostics segment, worldwide revenues for the quarter were \$434 million, representing an increase of 1 percent from the prior year period. The Preanalytical Systems unit of the segment reported revenue growth of 11 percent, benefiting from both BD Vacutainer® Push Button Blood Collection Set sales in the current year's quarter and a favorable comparison to the prior year's revenues, which were negatively impacted by reductions in inventory by a major U.S. distributor. U.S. sales of safety-engineered products totaled \$97 million compared with \$79 million in the prior year's quarter. For the six-month period ended March 31, 2006, U.S. sales of safety-engineered products totaled \$193 million compared with \$165 million in the prior year's period. Included in Preanalytical Systems revenues were international sales of safety-engineered products of \$55 million compared with \$47 million in the prior year's quarter. For the six-month period ended March 31, 2006, international sales of safety-engineered products totaled \$107 million compared with \$91 million in the prior year's period. Second quarter revenues in the Diagnostic Systems unit of the segment declined 8%, despite strong sales from diagnostic instrument platforms. For the most part, this decline in revenues was due to a relatively mild flu season in fiscal 2006 compared with 2005, in both Japan and the U.S. To a lesser extent, second quarter revenues were negatively impacted by the timing of early sales of flu diagnostic tests in the first fiscal quarter of 2006 and a challenging comparison to exceptionally strong sales of flu diagnostic tests in the prior year's quarter in Japan. For the six-month period ended March 31, 2006, the BD Diagnostics segment reported 4 percent revenue growth.

In the BD Biosciences segment, worldwide revenues from continuing operations for the quarter were \$220 million, representing an increase of 8 percent from the prior year period. Flow cytometry instrument and reagent sales continued to be the primary growth contributors. Sales in the Discovery Labware unit as well as sales of cell imaging products also contributed to sales growth. For the six-month period ended March 31, 2006, the BD Biosciences segment reported 9 percent revenue growth, representing continued strong sales of flow cytometry instruments and reagents.

Geographic Results

Second quarter revenues in the U.S. were \$702 million, representing an increase of 11 percent over the prior year period. Revenues outside the U.S. were \$748 million, representing an increase of 2 percent over the prior year period, and reflected an estimated 5 percent unfavorable impact from foreign currency translation.

For the six-month period ended March 31, 2006, revenues in the U.S. were \$1.383 billion, representing an increase of 10 percent over the prior year period. Revenues outside of the U.S. were \$1.481 billion, representing an increase of 6 percent over the prior year period, and reflected an estimated 4 percent unfavorable impact from foreign currency translation.

Fiscal 2006 Outlook for Third and Fourth Quarters and Full Year

The following analysis of estimated diluted earnings per share from continuing operations for the third and fourth fiscal quarters and full fiscal year identifies specified items that affect the comparability of results between periods.

(Table 2)	Three Months Ended June 30,			Three Months Ended September 30,			Twelve Months Ended September 30,		
	FY2006	FY2005	% Incr.	FY2006	FY2005	% Incr.	FY2006	FY2005	% Incr.
	(Estimated)			(Estimated)			(Estimated)		
Diluted EPS from Continuing Operations:⁽¹⁾	\$ 0.76-\$ 0.78	\$ 0.73	4-7%	\$ 0.80-\$ 0.82	\$ 0.47	70-74%	\$ 3.01-\$3.05	\$ 2.66	13-15%
Specified Items:									
Insurance Settlements ⁽²⁾	—	—		—	—		(0.04)	—	
In-Process Research and Development Charge ⁽³⁾	—	—		—	—		0.21	—	
Tax Examinations ⁽⁴⁾	—	—		—	—		—	(0.04)	
Tax Rate Impact ⁽⁵⁾	—	0.01		—	0.02		—	—	
Repatriation Tax Charge ⁽⁶⁾	—	—		—	0.27		—	0.27	
Rounding	—	—		—	—		—	(0.01)	
	—	0.01		—	0.29		0.17	0.22	
Diluted EPS from Continuing Operations Excluding Specified Items:⁽¹⁾	\$ 0.76-\$ 0.78	\$ 0.74	3-5%	\$ 0.80-\$ 0.82	\$ 0.76	5-8%	\$ 3.18-\$ 3.22	\$ 2.88	10-12%

- (1) Includes the effect on estimated diluted earnings per share from continuing operations of a 3 cent reduction in each of the third and fourth quarters and a 7 cent reduction in the twelve-month period ended September 30, 2006 relating to GeneOhm operations.
- (2) Represents the effect on estimated diluted earnings per share from continuing operations of 2 cents in each of the first and second quarter of fiscal 2006 related to proceeds received from insurance settlements regarding the Company's previously owned latex glove business.
- (3) Represents the effect on estimated diluted earnings per share from continuing operations of the in-process research and development charge recorded in the second quarter of fiscal 2006 related to the GeneOhm acquisition.
- (4) Represents the effect on diluted earnings per share from continuing operations of the reversal of tax reserves in the first fiscal quarter of 2005 in connection with the conclusion of tax examinations in four non-U.S. jurisdictions.
- (5) Represents the effect on diluted earnings per share from continuing operations of tax-related events that caused the quarterly tax rate to vary from the then expected effective tax rate for fiscal year 2005.
- (6) Included in diluted earnings per share from continuing operations for the fourth quarter of fiscal 2005 is 27 cents per diluted share substantially related to the impact on taxes of the planned repatriation of \$1.3 billion of foreign earnings under the provisions of the American Jobs Creation Act.

As illustrated in Table 2, the Company estimates that diluted earnings per share from continuing operations, including the expected dilutive impact on operating results from the acquisition, will increase approximately 3-5 percent for the third fiscal quarter of 2006 over diluted earnings per share from continuing operations, excluding specified items, of 74 cents for the third fiscal quarter of 2005. Excluding the expected dilutive impact of 3 cents on operating results from the acquisition, diluted earnings per share from continuing operations for the third fiscal quarter of 2006 are expected to be in the 79 to 81 cent range, representing an increase of 7-9 percent over diluted earnings per share from continuing operations, excluding specified items, of 74 cents for the third fiscal quarter of 2005.

The Company also estimates that diluted earnings per share from continuing operations, including the expected dilutive impact on operating results from the acquisition, will increase approximately 5-8 percent for the fourth fiscal quarter of 2006 over diluted earnings per share from continuing operations, excluding specified items, of 76 cents for the fiscal year 2005. Excluding the expected dilutive impact of 3 cents on operating results from the acquisition, diluted earnings per share from continuing operations for the fourth fiscal quarter of 2006 are expected to be in the 83 to 85 cent range, representing an increase of 9-12 percent over diluted earnings per share from continuing operations, excluding specified items, of 76 cents for the fourth fiscal quarter of 2005.

For the full fiscal year 2006, the Company estimates that diluted earnings per share from continuing operations, excluding specified items, and including the expected dilutive impact on operating results from the acquisition, are expected to be in the \$3.18 to \$3.22 range, representing an increase of approximately 10-12 percent over diluted earnings per share from continuing operations, excluding

specified items, of \$2.88 for the fiscal year 2005. Diluted earnings per share from continuing operations for the full year 2006, excluding specified items and the expected dilutive impact of 7 cents on operating results from the acquisition, are expected to be in the \$3.25 to \$3.29 range, representing an increase of 13-14 percent over diluted earnings per share from continuing operations, excluding specified items, of \$2.88 for the fiscal year 2005.

Conference Call Information

A conference call regarding BD's second fiscal quarter results and its expectations for the third and fourth fiscal quarters will be broadcast live on BD's website, www.bd.com/investors, at 10:00 a.m. (ET) Wednesday, April 26, 2006. The conference call will be available for replay on BD's website www.bd.com/investors, or at 1-800-272-5921 (domestic) and 1-402-220-9717 (international) through the close of business on Wednesday, May 3, 2006.

This news release contains certain non-GAAP financial measures. A reconciliation of these and other measures to the comparable GAAP measures is included in this release and in the attached financial tables.

About BD

BD, a leading global medical technology company that makes and sells medical devices, instrumented systems and reagents, is dedicated to improving people's health throughout the world. BD is focused on improving drug therapy, enhancing the quality and speed of diagnosing infectious diseases, and advancing research and discovery of new drugs and vaccines. The Company's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs more than 25,000 people in approximately 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, industry and the general public. For more information, please visit www.bd.com.

This press release, including the section entitled "Fiscal 2006 Outlook for Third and Fourth Quarters and Full Year," contains certain estimates and other forward-looking statements (as defined under Federal securities laws) regarding BD's performance, including future revenues, earnings per share and income, or events or developments that BD expects to occur or anticipates occurring in the future. All such statements are based upon current expectations of BD and involve a number of business risks and uncertainties. Actual results could vary materially from anticipated results described, implied or projected in any forward-looking statement. With respect to forward-looking statements contained herein, factors that could cause actual results to vary materially from any forward-looking statement include, but are not limited to: competitive factors; pricing and market share pressures; changes in interest or foreign currency exchange rates; difficulties inherent in product development and delays in product introductions; changes in regional, national or foreign economic conditions; further increases in energy costs and their effect on, among other things, the cost of producing BD's products; fluctuations in costs and availability of raw materials and in BD's ability to maintain favorable supplier arrangements and relationships; uncertainties of litigation (as described in BD's filings with the Securities and Exchange Commission); the effects of potential pandemic diseases; changes in healthcare or other governmental regulation; and issuance of new or revised accounting standards, as well as other factors discussed in this press release and in BD's filings with the Securities and Exchange Commission. We do not intend to update any forward-looking statements to reflect events or circumstances after the date hereof except as required by applicable laws or regulations.

BECTON DICKINSON AND COMPANY
CONSOLIDATED INCOME STATEMENTS
(Unaudited; Amounts in thousands, except per-share data)

	2006	Three Months Ended March 31, 2005	% Change
REVENUES	\$ 1,449,317	\$ 1,365,530	6.1
Cost of products sold	710,635	678,018	4.8
Selling and administrative	369,779	366,339	0.9
Research and development	129,099 (1)	65,988	95.6
TOTAL OPERATING COSTS AND EXPENSES	1,209,513	1,110,345	8.9
OPERATING INCOME	239,804	255,185	(6.0)
Interest expense	(19,805)	(13,044)	51.8
Interest income	16,991	8,488	NM
Other expense, net	(451)	(2,242)	(79.9)
INCOME FROM CONTINUING OPERATIONS BEFORE INCOME TAXES	236,539	248,387	(4.8)
Income tax provision	80,301	61,878	29.8
INCOME FROM CONTINUING OPERATIONS	156,238	186,509	(16.2)
(LOSS) INCOME FROM DISCONTINUED OPERATIONS NET OF INCOME TAX (BENEFIT) PROVISION OF \$(1,330) AND \$1,015, RESPECTIVELY	(2,170) (2)	1,641	NM
NET INCOME	\$ 154,068	\$ 188,150	(18.1)
EARNINGS PER SHARE			
Basic:			
Income from continuing operations	\$ 0.63	\$ 0.74	(14.9)
(Loss) income from discontinued operations	\$ (0.01)	\$ 0.01	NM
Net income (3)	\$ 0.62	\$ 0.74	(16.2)
Diluted:			
Income from continuing operations	\$ 0.60	\$ 0.71	(15.5)
(Loss) income from discontinued operations	\$ (0.01)	\$ 0.01	NM
Net income (3)	\$ 0.60	\$ 0.72	(16.7)
AVERAGE SHARES OUTSTANDING			
Basic	248,088	253,427	
Diluted	258,299	262,016	

NM - Not Meaningful

- (1) Includes the in-process research and development ("IPR&D") charge related to the GeneOhm acquisition.
- (2) Represents certain adjustments relating to the divestiture of Clontech.
- (3) Total per share amounts may not add due to rounding.

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL INFORMATION
Three Months Ended March 31,
(Unaudited; Amounts in thousands, except per-share data)

	2006			
	As Reported	Insurance Settlement (1)	GeneOhm IPR&D (2)	Excluding Items
Selling and administrative as a % of revenues	369,779 25.5%	10,000	—	379,779 26.2%
Research and development as a % of revenues	129,099 8.9%	—	(53,300)	75,799 5.2%
Operating Income as a % of revenues	239,804 16.5%	(10,000)	53,300	283,104 19.5%
Income taxes effective tax rate	80,301 33.9%	(3,800)	—	76,501 27.3%
Income from continuing operations as a % of revenues	156,238 10.8%	(6,200)	53,300	203,338 14.0%
<u>Diluted earnings per share</u>				
Income from continuing operations	\$ 0.60	\$ (0.02)	\$ 0.21	\$ 0.79

(1) Represents the effect in the second fiscal quarter of 2006 related to proceeds received from insurance settlements in connection with the Company's previously owned latex glove business.

(2) Represents the in-process research and development ("IPR&D") charge related to the GeneOhm acquisition.

BECTON DICKINSON AND COMPANY
CONSOLIDATED INCOME STATEMENTS
(Unaudited; Amounts in thousands, except per-share data)

	2006	Six Months Ended March 31, 2005	% Change
REVENUES	\$ 2,863,378	\$ 2,653,899	7.9
Cost of products sold	1,386,376	1,312,519	5.6
Selling and administrative	737,653	707,427	4.3
Research and development	198,424 (1)	128,071	54.9
TOTAL OPERATING COSTS AND EXPENSES	2,322,453	2,148,017	8.1
OPERATING INCOME	540,925	505,882	6.9
Interest expense	(36,565)	(27,371)	33.6
Interest income	31,662	13,693	NM
Other expense, net	(1,614)	(5,103)	(68.4)
INCOME FROM CONTINUING OPERATIONS BEFORE INCOME TAXES	534,408	487,101	9.7
Income tax provision	160,310	106,194	51.0
INCOME FROM CONTINUING OPERATIONS	374,098	380,907	(1.8)
(LOSS) INCOME FROM DISCONTINUED OPERATIONS NET OF INCOME TAX (BENEFIT) PROVISION OF \$(1,330) AND \$1,638, RESPECTIVELY	(2,170) (2)	2,594	NM
NET INCOME	\$ 371,928	\$ 383,501	(3.0)
EARNINGS PER SHARE			
Basic:			
Income from continuing operations	\$ 1.51	\$ 1.51	—
(Loss) income from discontinued operations	\$ (0.01)	\$ 0.01	NM
Net income	\$ 1.50	\$ 1.52	(1.3)
Diluted:			
Income from continuing operations	\$ 1.45	\$ 1.45	—
(Loss) income from discontinued operations	\$ (0.01)	\$ 0.01	NM
Net income (3)	\$ 1.45	\$ 1.46	(0.7)
AVERAGE SHARES OUTSTANDING			
Basic	248,067	252,317	
Diluted	257,145	262,393	

NM - Not Meaningful

- (1) Includes the in-process research and development ("IPR&D") charge related to the GeneOhm acquisition.
- (2) Represents certain adjustments relating to the divestiture of Clontech.
- (3) Total per share amounts may not add due to rounding.

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL INFORMATION

(Unaudited; Amounts in thousands, except per-share data)

	2006			
	As Reported	Insurance Settlement (1)	GeneOhm IPR&D (2)	Excluding Items
Selling and administrative as a % of revenues	737,653 25.8%	17,000	—	754,653 26.4%
Research and development as a % of revenues	198,424 6.9%	—	(53,300)	145,124 5.1%
Operating Income as a % of revenues	540,925 18.9%	(17,000)	53,300	577,225 20.2%
Income taxes effective tax rate	160,310 30.0%	(6,460)	—	153,850 27.0%
Income from continuing operations as a % of revenues	374,098 13.1%	(10,540)	53,300	416,858 14.6%
<u>Diluted earnings per share</u>				
Income from continuing operations	\$ 1.45	\$ (0.04)	\$ 0.21	\$ 1.62

(1) Represents the effect in 2006 related to proceeds received from insurance settlements in connection with the Company's previously owned latex glove business.

(2) Represents the in-process research and development ("IPR&D") charge related to the GeneOhm acquisition.

	2005			
	As Reported	Tax Examinations (4)	Tax Rate Impact (5)	Excluding Charges
Income taxes effective tax rate	106,194 21.8%	11,265	6,240	123,699 25.4%
Income from continuing operations as a % of revenues	380,907 14.4%	(11,265)	(6,240)	363,402 13.7%
<u>Diluted earnings per share</u>				
Income from continuing operations (3)	\$ 1.45	\$ (0.04)	\$ (0.02)	\$ 1.38

(3) Total per share amounts may not add due to rounding.

(4) Relates to the reversal of tax reserves in the first fiscal quarter 2005 in connection with the conclusion of tax examinations in four non-U.S. jurisdictions.

(5) Represents the effect on diluted earnings per share from continuing operations of tax-related events that caused the quarterly tax rate to vary from the then expected effective tax rate for fiscal year 2005.

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY SEGMENT AND GEOGRAPHIC AREA
(Unaudited; Amounts in thousands)

	Three Months Ended March 31,		% Change
	2006	2005	
<u>BD MEDICAL</u>			
United States	\$ 373,316	\$ 330,044	13.1
International	422,022	401,621	5.1
TOTAL	\$ 795,338	\$ 731,665	8.7
<u>BD DIAGNOSTICS</u>			
United States	\$ 232,913	\$ 213,175	9.3
International	201,166	216,594	(7.1)
TOTAL	\$ 434,079	\$ 429,769	1.0
<u>BD BIOSCIENCES</u>			
United States	\$ 95,315	\$ 86,947	9.6
International	124,585	117,149	6.3
TOTAL	\$ 219,900	\$ 204,096	7.7
<u>TOTAL REVENUES</u>			
United States	\$ 701,544	\$ 630,166	11.3
International	747,773	735,364	1.7
TOTAL	\$ 1,449,317	\$ 1,365,530	6.1

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY SEGMENT AND GEOGRAPHIC AREA
(Unaudited; Amounts in thousands)

	2006	Six Months Ended March 31, 2005	% Change
<u>BD MEDICAL</u>			
United States	\$ 739,899	\$ 659,698	12.2
International	826,139	765,789	7.9
TOTAL	\$ 1,566,038	\$ 1,425,487	9.9
<u>BD DIAGNOSTICS</u>			
United States	\$ 462,001	\$ 431,883	7.0
International	415,932	411,669	1.0
TOTAL	\$ 877,933	\$ 843,552	4.1
<u>BD BIOSCIENCES</u>			
United States	\$ 180,629	\$ 162,644	11.1
International	238,778	222,216	7.5
TOTAL	\$ 419,407	\$ 384,860	9.0
<u>TOTAL REVENUES</u>			
United States	\$ 1,382,529	\$ 1,254,225	10.2
International	1,480,849	1,399,674	5.8
TOTAL	\$ 2,863,378	\$ 2,653,899	7.9

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Three Months Ended March 31,
(Unaudited; Amounts in thousands)

	United States		
	2006	2005	% Change
BD MEDICAL			
Medical Surgical Systems	\$ 220,050	\$ 203,671	8.0
Diabetes Care	115,726	94,482	22.5
Pharmaceutical Systems	32,028	26,772	19.6
Ophthalmic Systems	5,512	5,119	7.7
TOTAL	\$ 373,316	\$ 330,044	13.1
BD DIAGNOSTICS			
Preanalytical Systems	\$ 125,412	\$ 107,050	17.2
Diagnostic Systems	107,501	106,125	1.3
TOTAL	\$ 232,913	\$ 213,175	9.3
BD BIOSCIENCES			
Discovery Labware	\$ 28,762	\$ 26,689	7.8
Immunocytometry Systems	46,226	41,051	12.6
Pharmingen	20,327	19,207	5.8
TOTAL	\$ 95,315	\$ 86,947	9.6
TOTAL UNITED STATES	\$ 701,544	\$ 630,166	11.3

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Three Months Ended March 31, (continued)
(Unaudited; Amounts in thousands)

	International				
	2006	2005	% Change		
			Reported	FX Neutral	FX Impact
BD MEDICAL					
Medical Surgical Systems	\$ 204,531	\$ 198,621	3.0	4.7	(1.7)
Diabetes Care	72,568	67,714	7.2	11.3	(4.1)
Pharmaceutical Systems	135,081	125,999	7.2	16.6	(9.4)
Ophthalmic Systems	9,842	9,287	6.0	13.4	(7.4)
TOTAL	\$ 422,022	\$ 401,621	5.1	9.8	(4.7)
BD DIAGNOSTICS					
Preanalytical Systems	\$ 101,449	\$ 97,785	3.7	8.2	(4.5)
Diagnostic Systems	99,717	118,809	(16.1)	(11.6)	(4.5)
TOTAL	\$ 201,166	\$ 216,594	(7.1)	(2.6)	(4.5)
BD BIOSCIENCES					
Discovery Labware	\$ 25,967	\$ 25,722	1.0	7.2	(6.2)
Immunocytometry Systems	77,348	72,709	6.4	12.1	(5.7)
Pharming	21,270	18,718	13.6	20.9	(7.3)
TOTAL	\$ 124,585	\$ 117,149	6.3	12.4	(6.1)
TOTAL INTERNATIONAL	\$ 747,773	\$ 735,364	1.7	6.5	(4.8)

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Three Months Ended March 31, (continued)
(Unaudited; Amounts in thousands)

	Total				
	2006	2005	% Change		
			Reported	FX Neutral	FX Impact
BD MEDICAL					
Medical Surgical Systems	\$ 424,581	\$ 402,292	5.5	6.4	(0.9)
Diabetes Care	188,294	162,196	16.1	17.8	(1.7)
Pharmaceutical Systems	167,109	152,771	9.4	17.2	(7.8)
Ophthalmic Systems	15,354	14,406	6.6	11.4	(4.8)
TOTAL	\$ 795,338	\$ 731,665	8.7	11.3	(2.6)
BD DIAGNOSTICS					
Preanalytical Systems	\$ 226,861	\$ 204,835	10.8	12.9	(2.1)
Diagnostic Systems	207,218	224,934	(7.9)	(5.5)	(2.4)
TOTAL	\$ 434,079	\$ 429,769	1.0	3.3	(2.3)
BD BIOSCIENCES					
Discovery Labware	\$ 54,729	\$ 52,411	4.4	7.5	(3.1)
Immunocytometry Systems	123,574	113,760	8.6	12.3	(3.7)
Pharming	41,597	37,925	9.7	13.3	(3.6)
TOTAL	\$ 219,900	\$ 204,096	7.7	11.2	(3.5)
TOTAL REVENUES	\$ 1,449,317	\$ 1,365,530	6.1	8.8	(2.7)

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Six Months Ended March 31,
(Unaudited; Amounts in thousands)

	United States		
	2006	2005	% Change
BD MEDICAL			
Medical Surgical Systems	\$ 442,316	\$ 419,177	5.5
Diabetes Care	226,127	182,943	23.6
Pharmaceutical Systems	60,428	46,821	29.1
Ophthalmic Systems	11,028	10,757	2.5
TOTAL	\$ 739,899	\$ 659,698	12.2
BD DIAGNOSTICS			
Preanalytical Systems	\$ 248,201	\$ 221,813	11.9
Diagnostic Systems	213,800	210,070	1.8
TOTAL	\$ 462,001	\$ 431,883	7.0
BD BIOSCIENCES			
Discovery Labware	\$ 56,462	\$ 50,783	11.2
Immunocytometry Systems	86,663	75,745	14.4
Pharmingen	37,504	36,116	3.8
TOTAL	\$ 180,629	\$ 162,644	11.1
TOTAL UNITED STATES	\$ 1,382,529	\$ 1,254,225	10.2

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Six Months Ended March 31, (continued)
(Unaudited; Amounts in thousands)

	International				
	2006	2005	% Change		
			Reported	FX Neutral	FX Impact
BD MEDICAL					
Medical Surgical Systems	\$ 410,428	\$ 392,679	4.5	5.0	(0.5)
Diabetes Care	145,863	137,931	5.8	8.9	(3.1)
Pharmaceutical Systems	250,444	216,635	15.6	23.8	(8.2)
Ophthalmic Systems	19,404	18,544	4.6	10.6	(6.0)
TOTAL	\$ 826,139	\$ 765,789	7.9	11.2	(3.3)
BD DIAGNOSTICS					
Preanalytical Systems	\$ 200,823	\$ 191,543	4.8	7.9	(3.1)
Diagnostic Systems	215,109	220,126	(2.3)	2.1	(4.4)
TOTAL	\$ 415,932	\$ 411,669	1.0	4.8	(3.8)
BD BIOSCIENCES					
Discovery Labware	\$ 47,976	\$ 48,591	(1.3)	3.8	(5.1)
Immunocytometry Systems	149,763	138,115	8.4	13.3	(4.9)
Pharming	41,039	35,510	15.6	21.5	(5.9)
TOTAL	\$ 238,778	\$ 222,216	7.5	12.5	(5.0)
TOTAL INTERNATIONAL	\$ 1,480,849	\$ 1,399,674	5.8	9.5	(3.7)

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Six Months Ended March 31, (continued)
(Unaudited; Amounts in thousands)

	Total				
	2006	2005	% Change		
			Reported	FX Neutral	FX Impact
BD MEDICAL					
Medical Surgical Systems	\$ 852,744	\$ 811,856	5.0	5.3	(0.3)
Diabetes Care	371,990	320,874	15.9	17.3	(1.4)
Pharmaceutical Systems	310,872	263,456	18.0	24.7	(6.7)
Ophthalmic Systems	30,432	29,301	3.9	7.6	(3.7)
TOTAL	\$ 1,566,038	\$ 1,425,487	9.9	11.6	(1.7)
BD DIAGNOSTICS					
Preanalytical Systems	\$ 449,024	\$ 413,356	8.6	10.0	(1.4)
Diagnostic Systems	428,909	430,196	(0.3)	1.9	(2.2)
TOTAL	\$ 877,933	\$ 843,552	4.1	5.9	(1.8)
BD BIOSCIENCES					
Discovery Labware	\$ 104,438	\$ 99,374	5.1	7.6	(2.5)
Immunocytometry Systems	236,426	213,860	10.6	13.7	(3.1)
Pharming	78,543	71,626	9.7	12.6	(2.9)
TOTAL	\$ 419,407	\$ 384,860	9.0	11.9	(2.9)
TOTAL REVENUES	\$ 2,863,378	\$ 2,653,899	7.9	9.8	(1.9)